TCRX shifts focus to in vivo TCR-T solid tumor programs
TCRX says a reorganization will advance two in vivo TCR-T solid tumor candidates to IND-enabling studies and plan Phase 1 trials in late 2027, while pausing or seeking partners for heme malignancy and autoimmune programs.
A major reorganization is shifting the company’s focus to in vivo TCR-T therapies for solid tumors, with two candidates now moving into IND-enabling studies and Phase 1 trials planned in late 2027. Heme malignancy and autoimmune programs are being paused or are seeking partners, and the company expects $55 million in cost savings.